FDA Clears Anavex IND for Blarcamesine in Fragile X Syndrome

Anavex received FDA clearance for its IND application evaluating blarcamesine for Fragile X syndrome, marking progress toward clinical trials for the condition with no approved treatments. This opens INDs for the drug in all three core indications.